Prostate Cancer

A new AI precision medicine test is being used to help clinicians better identify a personalized treatment plan to treat patients with prostate cancer.

The FDA has granted fast track designation to HLD-0915 for metastatic castration-resistant prostate cancer.

About one in six men with grade group 1 prostate cancer have higher-risk disease, showing outcomes vary and biopsy grade may underestimate risk.

After my cancer diagnosis, I planned to go it alone but found unconditional acceptance from the cancer community once I took the first step.

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on the phase 2 trial.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will benefit from intensified treatment.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural causes than from their cancer.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic castration-sensitive prostate cancer.

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data on the role of AI in care.

I was diagnosed with testicular cancer at 20. I’ve learned to embrace the pauses in life and stand proud as a survivor who won’t be ignored.

Dr. Ravi Munver explained that, for patients who are recently diagnosed with prostate cancer, it is important to explore treatment option with their care.

Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic lesion.

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.

Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.

Dr. Alicia Morgans discussed complications associated with ADT in prostate cancer, and how men can still maintain quality of life regardless.

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.

Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.

Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining treatment with PARP inhibitors.

A powerful new ally is emerging in cancer care: artificial intelligence.

The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate cancer, respectively.

Dr. Kelly Stratton answered the most frequently asked questions in prostate cancer regarding localized prostate cancer care, including surgery and focal therapy.

Dr. Kelly Stratton answers the most frequently asked questions in prostate cancer regarding risk for recurrence, progression and treatment options.

Managing fatigue, sleep, urinary symptoms and depression is key to improving cognitive function in those receiving radiation therapy for prostate cancer.